A study testing whether a new weekly shot from Boehringer Ingelheim, survodutide, can improve fatty liver disease.

Who can join

Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

What you take

survodutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 4.6 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: LIVERAGE - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis.

Primary condition: Metabolic Dysfunction Associated Steatohepatitis.

Who can join, in detail

Key inclusion criteria

• Male or female adults >=18 years of age at the time of screening, and at least the legal age of consent in countries where it is >18 years
• Body mass index (BMI) >=27 kg/m2(>=25 kg/m2 for Asian trial participants)
• Compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
• Magnetic resonance imaging proton density fat fraction (MRI-PDFF) fat fraction >=5% or FibroScan with controlled attenuation parameter (CAP) >=288 dB/m, obtained during the screening period or a historic MRI-PDFF <=12 weeks prior to randomisation (except for patients with 'cryptogenic cirrhosis' where MRI-PDFF <5% or FibroScan with CAP <288 dB/m is allowed). This inclusion criterion does not apply for participants with a recent (<=12 months prior to randomisation) liver biopsy showing steatosis/steatohepatitis.
• Further apply.

Key exclusion criteria

• Current or history (<5 years) of significant alcohol consumption, defined as an average of >140 g/week in female patients and >210 g/week in male patients, for a period of >3 consecutive months, or an inability to reliably quantify alcohol consumption based upon judgment of the investigator.
• Model of end-stage liver Disease (MELD) score >12 due to liver disease
• History or current (i.e. at screening) hepatic decompensation event of any of the following but not limited to:
• Portal hypertension-related upper gastrointestinal (GI) bleeding
• Ascites

Where this study is enrolling

This trial has 124 US sites across 25 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2024-11-07. Expected completion: 2029-06-05. Last updated on ClinicalTrials.gov: 2026-05-28.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact